Increased anti-KIR4.1 antibodies in multiple sclerosis: Could it be a marker of disease relapse?

Multiple Sclerosis Journal

Volumn 21, Issue 5, 2015, Pages 572-579

  Brill, Livnat ^a   Goldberg, Lotem ^b   Karni, Arnon ^a   Petrou, Panayiota ^a   Abramsky, Oded ^a   Ovadia, Haim ^b   Ben Hur, Tamir ^a   Karussis, Dimitrios ^a   Vaknin Dembinsky, Adi ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Autoimmune disease; biomarker; immunoassay; immunology; KIR4.1; multiple sclerosis; neuromyelitis optica; potassium channel; relapse

Indexed keywords

ANTIBODY; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR4.1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; KIR4.1 ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE EXACERBATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; RELAPSE; REMISSION; WESTERN BLOTTING; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION;

EID: 84938482935     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514551779     Document Type: Article

References (41)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000 ; 343: 938-952
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
3. McFarland HF, Martin R. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol. 2007 ; 8: 913-919
4. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: In situ evidence for antibody-And complement-mediated demyelination. Ann Neurol. 1998 ; 43: 465-471
5. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: An overview. Brain Pathol. 2007 ; 17: 210-218
6. Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008 ; 63: 16-25
7. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688
8. Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr Opin Neurol. 2009 ; 22: 226-232
9. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004 ; 364: 2106-2112
10. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005 ; 202: 473-477
11. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013 ; 81: 1197-204
12. Kitley J, Leite MI, Kuker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol. 2013 ; 70: 1375-1381
13. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012 ; 367: 115-123
14. Butt AM, Kalsi A. Inwardly rectifying potassium channels (Kir) in central nervous system glia: A special role for Kir4.1 in glial functions. J Cell Mol Med. 2006 ; 10: 33-44
15. Verkhratsky A, Steinhauser C. Ion channels in glial cells. Brain Res Brain Res Rev. 2000 ; 32: 380-412
16. Kofuji P, Newman EA. Potassium buffering in the central nervous system. Neuroscience. 2004 ; 129: 1045-1056
17. Newman EA. High potassium conductance in astrocyte endfeet. Science. 1986 ; 233: 453-454
18. Nagelhus EA, Horio Y, Inanobe A, et al. Immunogold evidence suggests that coupling of K+ siphoning and water transport in rat retinal Muller cells is mediated by a coenrichment of Kir4.1 and AQP4 in specific membrane domains. Glia. 1999 ; 26: 47-54
19. Tait MJ, Saadoun S, Bell BA, et al. Water movements in the brain: Role of aquaporins. Trends Neurosci. 2008 ; 31: 37-43
20. Connors NC, Adams ME, Froehner SC, et al. The potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex via alpha-syntrophin in glia. J Biolog Chem. 2004 ; 279: 28387-28392
21. Monce NM, Bogusky RT, Cappel NN. An enzyme immunoassay screening test for the detection of total antinuclear antibodies. J Clin Lab Anal. 1991 ; 5: 439-442
22. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
23. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
24. Garcia-Caballero A, Dang Y, He H, et al. ENaC proteolytic regulation by channel-Activating protease 2. J General Physiol. 2008 ; 132: 521-535
25. Masaki H, Wakayama Y, Hara H, et al. Immunocytochemical studies of aquaporin 4, Kir4.1 and alpha1-syntrophin in the astrocyte endfeet of mouse brain capillaries. Acta Histochem Cytochem. 2010 ; 43: 99-105
26. Watanabe M, Yamasaki R, Kawano Y, et al. Anti-KIR4.1 antibodies in Japanese patients with idiopathic central nervous system demyelinating diseases. Clin Exp Neuroimmunol. 2013 ; 4: 241-242
27. Nerrant E, Salsac C, Charif M, et al. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler. 2014 ;:
28. Brickshawana A, Hinson SR, Romero MF, et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: A comparative study. Lancet Neurol. 2014 ; 13: 795-806
29. Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with anti-muscle-specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry. 2007 ; 78: 417-418
30. Yeh JH, Chen WH, Chiu HC, et al. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology. 2004 ; 62: 2131-2132
31. Kraus V, Srivastava R, Kalluri SR, et al. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology. 2014 ; 82: 470-473
32. Weinshenker BG. Neuromyelitis optica is distinct from multiple sclerosis. Arch Neurol. 2007 ; 64: 899-901
33. Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurolog Sci. 2010 ; 291: 52-56
34. Cayrol R, Saikali P, Vincent T. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica. Ann NY Acad Sci. 2009 ; 1173: 478-486
35. Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008 ; 205: 2473-2481
36. Wen H, Nagelhus EA, Amiry-Moghaddam M, et al. Ontogeny of water transport in rat brain: Postnatal expression of the aquaporin-4 water channel. Eur J Neurosci. 1999 ; 11: 935-945
37. Pittock SJ, Lennon VA, De Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008 ; 65: 78-83
38. Vaknin-Dembinsky A, Abramsky O, Petrou P, et al. Myasthenia gravis-Associated neuromyelitis optica-like disease: An immunological link between the central nervous system and muscle?. Arch Neurol. 2011 ; 68: 1557-1561
39. Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients. Neurology. 78: 1601-1607
40. O'Connor KC, Lopez-Amaya C, Gagne D, et al. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol. 2010 ; 223: 92-99
41. Tomassini V, De Giglio L, Reindl M, et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler. 2007 ; 13: 1086-1094